Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Molecular Targets
  11. Advancing Antibody-drug Conjugates: Precision Oncology Approaches For Breast And Pancreatic Cancers

Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers

Dhanvin R Yajaman1,2, Youngman Oh1,2, Jose G Trevino2,3

  • 1Department of Pathology, Virginia Commonwealth University, Richmond, VA 23284, USA.

Cancers
|June 13, 2025

Related Experiment Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.6K

View abstract on PubMed

Summary
This summary is machine-generated.

Antibody-drug conjugates (ADCs) show promise in treating triple-negative breast cancer (TNBC), but face challenges in pancreatic ductal adenocarcinoma (PDAC) due to tumor microenvironment and antigen issues.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic agents for targeted cancer therapy.
  • Recent advancements focus on payload, linker, and antibody engineering for improved efficacy.
  • ADCs represent an innovative strategy in cancer treatment.

Purpose of the Study:

  • To review recent advancements and challenges in antibody-drug conjugate (ADC) development.
  • To examine the role of ADC components in pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC).
  • To compare the efficacy of ADCs in pancreatic and breast cancers.

Main Methods:

  • Review of studies on ADC development, including payload, linker, and antibody engineering.
  • Examination of ADC internalization and its role in PDAC and TNBC.
Keywords:
antibody–drug conjugates (ADCs)cancer biomarkersmonoclonal antibodiespancreatic ductal adenocarcinoma (PDAC)

Related Experiment Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.6K
  • Comparative analysis of ADC efficacy in pancreatic and breast cancers.

    • Main Results:

    • ADCs like sacituzumab govitecan and trastuzumab deruxtecan have improved progression-free survival in advanced TNBC.
    • PDAC ADC development is hindered by low antigen density and poor internalization.
    • Despite target engagement, PDAC ADCs have not yet achieved significant clinical efficacy or regulatory approval.

    Conclusions:

    • ADCs have significantly advanced TNBC treatment options.
    • PDAC remains a challenging target for ADCs due to its stroma-rich microenvironment and antigen limitations.
    • Tailor-made ADC designs are crucial for enhancing cancer treatment outcomes and advancing precision oncology.
    precision oncology
    targeted cancer therapy
    triple-negative breast cancer (TNBC)